Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs letrozole vs triptorelin for uterine myoma
IRCT20211212053372N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Fibromyoma (LM) comparing Letrozole, Cabergoline and Triptorelin (3 arms). Primary endpoints: Uterine size, Uterine bleeding amount and 1 more. Started Jan 2022; status: completed.
02
Drugs
cabergolineletrozoletriptorelin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20211212053372N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211212053372N1.